These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38155480)

  • 1. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets.
    Vernemmen AIP; Samarska IV; Speel EM; Riedl RG; Goudkade D; de Bruïne AP; Wouda S; van Marion AM; Verlinden IV; van Lijnschoten I; Friederich P; Winnepenninckx VJL; Zur Hausen A; Sciot RME; van den Hout MFCM
    Histopathology; 2024 Apr; 84(5):794-809. PubMed ID: 38155480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
    Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma.
    Lee JC; Li CF; Huang HY; Zhu MJ; Mariño-Enríquez A; Lee CT; Ou WB; Hornick JL; Fletcher JA
    J Pathol; 2017 Feb; 241(3):316-323. PubMed ID: 27874193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of kinase gene rearrangements in a large series of paediatric inflammatory myofibroblastic tumours.
    Preobrazhenskaya EV; Suleymanova AM; Bizin IV; Zagrebin FA; Romanko AA; Saitova ES; Mulkidzhan RS; Imyanitov EN
    Histopathology; 2023 Jul; 83(1):109-115. PubMed ID: 37071060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.
    Lovly CM; Gupta A; Lipson D; Otto G; Brennan T; Chung CT; Borinstein SC; Ross JS; Stephens PJ; Miller VA; Coffin CM
    Cancer Discov; 2014 Aug; 4(8):889-95. PubMed ID: 24875859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review.
    Zhang L; Luan L; Shen L; Xue R; Huang J; Su J; Huang Y; Xu Y; Wang X; Shao Y; Ji Y; Xu C; Hou Y
    Virchows Arch; 2023 Mar; 482(3):567-580. PubMed ID: 36624188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
    Mariño-Enríquez A; Wang WL; Roy A; Lopez-Terrada D; Lazar AJ; Fletcher CD; Coffin CM; Hornick JL
    Am J Surg Pathol; 2011 Jan; 35(1):135-44. PubMed ID: 21164297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
    Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
    Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of ALK Fusions in Uncommon Inflammatory Myofibroblastic Tumors With ALK IHC Positivity but FISH-Equivocal Findings by Targeted RNA Sequencing.
    Yao Q; Bai Q; Zhang X; Ji G; Chang H; Cai X; Yu L; Wang J; Zhu X; Zhou X
    Arch Pathol Lab Med; 2022 Oct; 146(10):1234-1242. PubMed ID: 35041745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
    Collins K; Ramalingam P; Euscher ED; Reques Llanos A; García A; Malpica A
    Am J Surg Pathol; 2022 Jan; 46(1):105-117. PubMed ID: 34138797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma.
    Jiang Q; Tong HX; Hou YY; Zhang Y; Li JL; Zhou YH; Xu J; Wang JY; Lu WQ
    Orphanet J Rare Dis; 2017 May; 12(1):97. PubMed ID: 28535796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary inflammatory myofibroblastic tumour of the liver: a clinicopathological and genetic study including a subset with ETV6::NTRK3 fusion.
    Han Q; Zhang Z; He X; Chen M; Pang X; Chen C; Du T; Zhang H
    Histopathology; 2023 May; 82(6):925-936. PubMed ID: 36748182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel CASC15-ALK and TFG-ROS1 Fusion Observed in Uterine Inflammatory Myofibroblastic Tumor.
    Chang B; Wang Z; Ren M; Yao Q; Zhao L; Zhou X
    Int J Gynecol Pathol; 2023 Sep; 42(5):451-459. PubMed ID: 36730016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
    Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
    Front Oncol; 2022; 12():761558. PubMed ID: 35237506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinicopathological features of inflammatory myofibroblastic tumor].
    Zhu Y; Ding Y; Song GX; Li X; Ding R; Fan QH; Gong QX
    Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):194-200. PubMed ID: 33677881
    [No Abstract]   [Full Text] [Related]  

  • 16. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
    Chang JC; Zhang L; Drilon AE; Chi P; Alaggio R; Borsu L; Benayed R; Travis WD; Ladanyi M; Antonescu CR
    J Thorac Oncol; 2019 May; 14(5):825-834. PubMed ID: 30550870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy.
    Baranov E; Winsnes K; O'Brien M; Voss SD; Church AJ; Janeway KA; DuBois SG; Davis JL; Al-Ibraheemi A
    Histopathology; 2022 Aug; 81(2):215-227. PubMed ID: 35543076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
    Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
    Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized targeted treatment in a case of a rare TFG::ROS1 fusion positive inflammatory myofibroblastic tumor (IMT).
    Sommer S; Schmutz M; Schaller T; Mayr P; Dintner S; Märkl B; Huss R; Golas MM; Kuhlen M; Jordan F; Claus R; Heinrich B
    Cancer Rep (Hoboken); 2024 Jan; 7(1):e1916. PubMed ID: 37950626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uterine inflammatory myofibroblastic tumor: First report of a ROS1 fusion.
    Bennett JA; Wang P; Wanjari P; Diaz L; Oliva E
    Genes Chromosomes Cancer; 2021 Dec; 60(12):822-826. PubMed ID: 34322931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.